# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-26-016763
Filing Date
2026-04-24
Accepted
2026-04-24 17:05:43
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | ny20064249x2_defa14a.htm | DEFA14A | 16587
2 |  | ny20064249x2_defa14aslide1.jpg | GRAPHIC | 1260065
3 |  | ny20064249x2_defa14aslide2.jpg | GRAPHIC | 1502872
| Complete submission text file | 0001140361-26-016763.txt |  | 3819494

Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38599 | Film No.: 26895610
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)